{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:57:24Z","timestamp":1791244644084,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["207814"],"award-info":[{"award-number":["207814"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["HO-17-18078"],"award-info":[{"award-number":["HO-17-18078"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.04.014","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T11:47:27Z","timestamp":1554983247000},"page":"2896-2909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-8837","authenticated-orcid":false,"given":"Ashleigh","family":"McGirr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Widenmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-0111","authenticated-orcid":false,"given":"Desmond","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Espi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Mrkvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Oostvogels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"McElhaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Haeussler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Thano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel S","family":"Newson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2019.04.014_b0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1155\/2010\/178036","article-title":"Management and prevention of herpes zoster: A Canadian perspective","volume":"21","author":"Boivin","year":"2010","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.014_b0010","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ncl.2008.03.011","article-title":"Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency","volume":"26","author":"Mueller","year":"2008","journal-title":"Neurol Clin"},{"key":"10.1016\/j.vaccine.2019.04.014_b0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2019.04.014_b0020","unstructured":"Zostavax Prescribing Information. 2018. Available from: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zostavax\/zostavax_pi2.pdf. [Accessed: April 2018]."},{"issue":"22","key":"10.1016\/j.vaccine.2019.04.014_b0025","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2019.04.014_b0030","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.014_b0035","unstructured":"Food and Drug Administration. BLA approval. 2017. Available from: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM581750.pdf. [Accessed: 23 April 2018]."},{"key":"10.1016\/j.vaccine.2019.04.014_b0040","unstructured":"Health Canada. Shingrix Product Monograph. 2017. Available from: https:\/\/ca.gsk.com\/media\/1350788\/shingrix_pm-2017-10-13.pdf. [Accessed: 26 July 2018]."},{"issue":"22","key":"10.1016\/j.vaccine.2019.04.014_b0045","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2019.04.014_b0050","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.04.014_b0055","first-page":"CD008858","article-title":"Vaccines for preventing herpes zoster in older adults","volume":"3","author":"Gagliardi","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1 Suppl","key":"10.1016\/j.vaccine.2019.04.014_b0060","first-page":"225","article-title":"A comparison of the immunogenicity of a live attenuated herpes zoster vaccine (ZV) and the recombinant gE\/AS01B candidate vaccine in older adults","volume":"198","author":"Weinberg","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.014_b0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2019.04.014_b0070","doi-asserted-by":"crossref","first-page":"k4029","DOI":"10.1136\/bmj.k4029","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis","volume":"363","author":"Tricco","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2019.04.014_b0075","unstructured":"ID Week. 2016. Available from: https:\/\/www.idweek.org\/. [Accessed: 30 July 2018]."},{"key":"10.1016\/j.vaccine.2019.04.014_b0080","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from: http:\/\/handbook.cochrane.org. [Accessed: April 2018]."},{"key":"10.1016\/j.vaccine.2019.04.014_b0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1741-7015-12-93","article-title":"A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer","volume":"12","author":"Cope","year":"2014","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.014_b0090","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res Synth Methods"},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.014_b0095","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/dme.13038","article-title":"Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Hata","year":"2016","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.014_b0100","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/21645515.2016.1232787","article-title":"Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged >\/=50 years when administered subcutaneously vs. intramuscularly","volume":"13","author":"Vink","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.014_b0105","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"Rucker","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.vaccine.2019.04.014_b0110","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Guidelines - Work Products. 2019. Available from: https:\/\/www.ich.org\/products\/guidelines.html. [Accessed: 31 January 2019."},{"key":"10.1016\/j.vaccine.2019.04.014_b0115","unstructured":"R\u00fccker G, Schwarzer G, Krahn U, K\u00f6nig J. netmeta: Network Meta-Analysis using Frequentist Methods. R package version 0.9-8. 2018. Available from: https:\/\/cran.r-project.org\/web\/packages\/netmeta\/index.html. [Accessed: 30 July 2018]."},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.014_b0120","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1473-3099(16)00133-X","article-title":"Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial","volume":"16","author":"Beals","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.04.014_b0125","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1086\/514265","article-title":"A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older","volume":"178","author":"Berger","year":"1998","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2019.04.014_b0130","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2019.04.014_b0135","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/ofid\/ofw194.77","article-title":"Quality of life impact of an investigational subunit adjuvanted herpes zoster vaccine in adults \u226550 years of age","volume":"3","author":"Curran","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.014_b0140","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.vaccine.2014.12.024","article-title":"Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged >\/=50 years: a randomised non-inferiority clinical trial","volume":"33","author":"Diez-Domingo","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.014_b0145","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/CVI.00310-07","article-title":"A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax","volume":"15","author":"Gilderman","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.014_b0150","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1532-5415.2007.01397.x","article-title":"Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older","volume":"55","author":"Kerzner","year":"2007","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"10.1016\/j.vaccine.2019.04.014_b0155","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4161\/hv.6.11.12852","article-title":"Concomitant administration of zoster and pneumococcal vaccines in adults >\/=60 years old","volume":"6","author":"MacIntyre","year":"2010","journal-title":"Hum Vaccin"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2019.04.014_b0160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ofid\/ofw194.40","article-title":"Efficacy, immunogenicity and safety of an investigational subunit adjuvanted herpes zoster vaccine in adults aged 60 years and older: results from the ZOE-50 and ZOE-70 efficacy studies","volume":"3","author":"McElhaney","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2019.04.014_b0165","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4161\/hv.7.11.17982","article-title":"Safety and tolerability of zoster vaccine in adults >\/=60 years old","volume":"7","author":"Murray","year":"2011","journal-title":"Hum Vaccin"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2019.04.014_b0170","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1086\/522159","article-title":"Vaccination against herpes zoster and postherpetic neuralgia","volume":"197","author":"Oxman","year":"2008","journal-title":"J Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2019.04.014_b0175","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/ofid\/ofw172.616","article-title":"Immunogenicity and safety of 2 doses of an investigational herpes zoster subunit vaccine administered 2, 6 or 12 months apart in adults 50 years and older: results of a phase III, randomized, open-label, multicenter trial","volume":"3","author":"Poder","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"27","key":"10.1016\/j.vaccine.2019.04.014_b0180","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1016\/j.vaccine.2015.04.090","article-title":"Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic\/maintenance corticosteroids","volume":"33","author":"Russell","year":"2015","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.014_b0185","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2019.04.014_b0190","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/ofid\/ofw172.614","article-title":"Randomized, phase III clinical trial to assess the immunogenicity and safety of an investigational subunit adjuvanted herpes zoster vaccine co-administered with a seasonal quadrivalent inactivated influenza vaccine in adults aged 50 years and older","volume":"3","author":"Schwarz","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2019.04.014_b0195","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","article-title":"Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial","volume":"152","author":"Simberkoff","year":"2010","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.014_b0200","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.vaccine.2006.10.027","article-title":"Safety and tolerability of a high-potency zoster vaccine in adults >\/= 50 or years of age","volume":"25","author":"Tyring","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.04.014_b0205","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.vaccine.2011.11.096","article-title":"Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults >\/=60 years of age","volume":"30","author":"Vermeulen","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.014_b0210","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4161\/hv.23412","article-title":"Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax(R)) in individuals aged >\/= 70 years: a randomized study of a single dose vs. two different two-dose schedules","volume":"9","author":"Vesikari","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.04.014_b0215","unstructured":"Advisory Committee on Immunization Practices. Summary Report, October 25-26, 2017. 2017. Available from: https:\/\/www.cdc.gov\/vaccines\/news\/newsltrs\/imwrks\/2017\/2017-10.html. [Accessed: 24 April 2018]."},{"key":"10.1016\/j.vaccine.2019.04.014_b0220","unstructured":"National Advisory Committee on Immunization. Updated Recommendations on the Use of Herpes Zoster Vaccines. 2018. Available from: https:\/\/ca.gsk.com\/en-ca\/media\/press-releases\/2018\/national-advisory-committee-on-immunization-naci-recommends-shingrix-for-the-prevention-of-shingles-for-adults-aged-50-and-up\/. [Accessed: 6 August 2018]."},{"key":"10.1016\/j.vaccine.2019.04.014_b0225","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","article-title":"Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial","volume":"169","author":"Leroux-Roels","year":"2016","journal-title":"Clin Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2019.04.014_b0230","doi-asserted-by":"crossref","first-page":"S746","DOI":"10.1093\/ofid\/ofy210.2141","article-title":"The impact of reactogenicity after administration of the recombinant zoster vaccine upon the physical functioning and quality of life of older adults","volume":"5","author":"Schmader","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.014_b0235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.04.014_b0240","unstructured":"Comit\u00e9 sur l'immunisation du Qu\u00e9bec. Avis sur la pertinence d\u2019ajouter la vaccination contre le zona au Programme qu\u00e9b\u00e9cois d\u2019immunisation. 2018. Available from: https:\/\/www.inspq.qc.ca\/sites\/default\/files\/publications\/2381_pertinence_vaccination_zona_programme_quebecois_immunisation.pdf. [Accessed: 6 August 2018]."},{"key":"10.1016\/j.vaccine.2019.04.014_b0245","first-page":"333","article-title":"St\u00e4ndige Impfkommission: Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut","volume":"34","author":"Robert Koch Institut","year":"2017","journal-title":"Epid Bull"},{"key":"10.1016\/j.vaccine.2019.04.014_b0250","first-page":"541","article-title":"Mitteilung der St\u00e4ndigen Impfkommission (STIKO) beim RKI. Wissenschaftliche Begr\u00fcndung zur Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff","volume":"50","author":"Robert Koch Institut","year":"2018","journal-title":"Epid Bull"},{"key":"10.1016\/j.vaccine.2019.04.014_b0255","unstructured":"Bresnitz E, Johnson K, Weiss T, Saddier P. A review of real-world effectiveness studies on the live zoster vaccine. 2018. 16th National Immunisation Conference, 05-07 June 2018, Adelaide, Australia. Available from: https:\/\/docs.wixstatic.com\/ugd\/a52314_3bb4bcf0ad0a462081e76c4b72556bae.pdf. [Accessed: 05 February 2019]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:31:17Z","timestamp":1759401077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19304554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":51,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19304554"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.014","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}